Page 1 | Search Results | The Hematologist | American Society of Hematology

Skip Nav Destination

1-18 of 18

Sort by

Sort Order Select

Articles

The Holy Grail of Second Complete Remission in Relapsed Pediatric T-acute Lymphoblastic Leukemia

Sarah K. Tasian, MD

The Hematologist (2024) 21 (1)

https://doi.org/10.1182/hem.V21.1.2024115

Published: 2024

Articles

The Brilliant Success of Blinatumomab for Babies With Acute Lymphoblastic Leukemia

Haley Newman, MD, Sarah K. Tasian, MD

The Hematologist (2023) 20 (6)

https://doi.org/10.1182/hem.V20.6.202365

Published: 2023

Articles

Taking the Pulse of ALL Maintenance Therapy

Sarah K. Tasian, MD

The Hematologist (2023) 20 (5)

https://doi.org/10.1182/hem.V20.5.202357

Published: 2023

Articles

A “Revu” of Initial Phase 1 Clinical Trial Results of Menin Inhibition in Patients with Relapsed/Refractory Acute Leukemias

Branko Cuglievan, MD, Sarah K. Tasian, MD

The Hematologist (2023) 20 (4)

https://doi.org/10.1182/hem.V20.4.2023412

Published: 2023

Articles

In Which Trial Do I Belong? The PedAL APAL2020SC and EuPAL 2021 Registry Sorting Hats for Relapsed/Refractory Pediatric Acute Leukemias

Andrew D Hughes, MD PhD, Sarah K Tasian, MD

The Hematologist (2023) 20 (3)

https://doi.org/10.1182/hem.V20.3.2023310

Published: 2023

Articles

Childhood ALL: Small Patients, Yet Everbigger Genetic Complexity

Sarah K. Tasian, MD

The Hematologist (2023) 20 (2)

https://doi.org/10.1182/hem.V20.2.202322

Published: 2023

Articles

Understanding the Ontogeny of Our Tiniest Patients With Leukemia

Sarah K. Tasian, MD

The Hematologist (2023) 20 (1)

https://doi.org/10.1182/hem.V20.1.2023113

Published: 2023

Articles

Agreeing to Agree: International Consensus Definitions of Complete Remission, Treatment Failure, and Relapse in Childhood Acute Lymphoblastic Leukemia

Yang-Yang Ding, MD, Sarah K. Tasian, MD

The Hematologist (2022) 19 (6)

https://doi.org/10.1182/hem.V19.6.202265

Published: 2022

Articles

The Ups and Downs of Leukemia in Children With Trisomy 21

Kaoru Takasaki, MD, Sarah K Tasian, MD

The Hematologist (2022) 19 (5)

https://doi.org/10.1182/hem.V19.5.2022510

Published: 2022

Articles

Targeting CD22 in Children With Relapsed B-ALL: At Least One Good Thing Happened in 2022

Holly Pariury, DO, Sarah K. Tasian, MD

The Hematologist (2022) 19 (4)

https://doi.org/10.1182/hem.V19.4.202246

Published: 2022

Articles

Do Not Pass on GO in Childhood KMT2A -Rearranged AML (and Collect 20% Improvement in EFS)

Anand Bhagwat, MD, PhD, Sarah K. Tasian, MD

The Hematologist (2022) 19 (3)

https://doi.org/10.1182/hem.V19.3.202238

Published: 2022

Articles

New Tricks and Old Dogs: Will the Addition of Venetoclax to Conventional Multidrug Chemotherapy Decrease Relapse Risk for Younger Adults With Newly Diagnosed AML?

Grace Egan, MD, Sarah K. Tasian, MD

The Hematologist (2022) 19 (2)

https://doi.org/10.1182/hem.V19.2.202224

Published: 2022

Articles

Combinatorial BCL-2 Inhibition for ALL of the Leukemias: The Sum Is More Than the Parts

Sarah K. Tasian, MD

The Hematologist (2022) 19 (1)

https://doi.org/10.1182/hem.V19.1.202218

Published: 2022

Articles

Phat Mass and Ph-like ALL: A Link Between Obesity and CRLF2 Rearrangements?

Sarah K. Tasian, MD

The Hematologist (2021) 18 (6)

https://doi.org/10.1182/hem.V18.6.202167

Published: 2021

Articles

Bacon-Wrapped Chemo: Can Liposomal Cytarabine/Daunomycin Improve Outcomes for Children With Newly Diagnosed AML Versus Conventional Therapy?

Adam J. Lamble, MD, Sarah K. Tasian, MD

The Hematologist (2021) 18 (5)

https://doi.org/10.1182/hem.V18.5.2021510

Published: 2021

Articles

Chemotherapy Drug Shortages in Pediatric Oncology: A Global Public Health Crisis Threatening Our Children

Lauren Pommert, MD, Sarah K. Tasian, MD

The Hematologist (2021) 18 (4)

https://doi.org/10.1182/hem.V18.4.2021412

Published: 2021

Articles

Take Your “Asparagus Medication,” Kids!

Shannon E. Conneely, MD, Sarah K. Tasian, MD

The Hematologist (2021) 18 (3)

Published: 2021

Articles

Immunotherapy and TKIs: Precision Agonism or Antagonism for Ph+ ALL?

Sarah K. Tasian, MD

The Hematologist (2021) 18 (2)

Published: 2021

NARROW

The Holy Grail of Second Complete Remission in Relapsed Pediatric T-acute Lymphoblastic Leukemia

The Brilliant Success of Blinatumomab for Babies With Acute Lymphoblastic Leukemia

Taking the Pulse of ALL Maintenance Therapy

A “Revu” of Initial Phase 1 Clinical Trial Results of Menin Inhibition in Patients with Relapsed/Refractory Acute Leukemias

In Which Trial Do I Belong? The PedAL APAL2020SC and EuPAL 2021 Registry Sorting Hats for Relapsed/Refractory Pediatric Acute Leukemias

Childhood ALL: Small Patients, Yet Everbigger Genetic Complexity

Understanding the Ontogeny of Our Tiniest Patients With Leukemia

Agreeing to Agree: International Consensus Definitions of Complete Remission, Treatment Failure, and Relapse in Childhood Acute Lymphoblastic Leukemia

The Ups and Downs of Leukemia in Children With Trisomy 21

Targeting CD22 in Children With Relapsed B-ALL: At Least One Good Thing Happened in 2022

Do Not Pass on GO in Childhood KMT2A -Rearranged AML (and Collect 20% Improvement in EFS)

New Tricks and Old Dogs: Will the Addition of Venetoclax to Conventional Multidrug Chemotherapy Decrease Relapse Risk for Younger Adults With Newly Diagnosed AML?

Combinatorial BCL-2 Inhibition for ALL of the Leukemias: The Sum Is More Than the Parts

Phat Mass and Ph-like ALL: A Link Between Obesity and CRLF2 Rearrangements?

Bacon-Wrapped Chemo: Can Liposomal Cytarabine/Daunomycin Improve Outcomes for Children With Newly Diagnosed AML Versus Conventional Therapy?

Chemotherapy Drug Shortages in Pediatric Oncology: A Global Public Health Crisis Threatening Our Children

Take Your “Asparagus Medication,” Kids!

Immunotherapy and TKIs: Precision Agonism or Antagonism for Ph+ ALL?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only